Lifecore (LFCR) Biomedical and PolyPeptide Laboratories announced the signing of a collaboration agreement aimed at providing an integrated, end-to-end solution for peptide-based pharmaceutical customers in the U.S. The collaboration will leverage PolyPeptide’s strong capabilities in peptide manufacturing and development in combination with Lifecore’s expertise in formulation, fill/finish, and packaging. The companies intend to work together to offer a seamless transition between drug substance and drug product, which is designed to enable customers to accelerate development timelines, reduce development costs and risks, and enjoy the reliability and regulatory alignment that comes with a fully U.S.-based supply chain.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFCR:
- Lifecore Biomedical, Inc. (LFCR) Q1 Earnings Cheat Sheet
- Lifecore Biomedical Approves New Cash Incentive Plan
- Hold Rating for Lifecore Biomedical Amid Strategic Progress and High Leverage Concerns
- Lifecore files to sell $150M of common stock, warrants
- Lifecore files to sell 20.46M shares of common stock for holders